JAZMINE LARSON: Open Payments
NPI 1578171211 · MERRILLVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,733 in 138 payments from 15 companies in 2025. Trend: 2023 $526 · 2024 $2,455 · 2025 $2,733
Food & beverage: $2,733
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $399 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $371 |
| ABBVIE INC. | 15 | $302 |
| E.R. Squibb & Sons, L.L.C. | 15 | $282 |
| Teva Pharmaceuticals USA, Inc. | 16 | $277 |
| Otsuka America Pharmaceutical, Inc. | 15 | $246 |
| Vanda Pharmaceuticals Inc. | 10 | $215 |
| Lundbeck LLC | 11 | $191 |
| Alkermes, Inc. | 9 | $173 |
| Axsome Therapeutics, Inc. | 4 | $87 |
Products named: INGREZZA, CAPLYTA, VRAYLAR, COBENFY, UZEDY, FANAPT, ARISTADA, REXULTI.
Industry payments across IN — which companies pay providers there.
